Kringle Pharma, Inc.
Announcement of Joint Research with Yokohama City University
Signed a joint research agreement with Yokohama City University, a public university corporation. Conducting efficacy evaluation of HGF for CIPN. Describes only a minor impact on business performance from R&D expenses.
Key Figures
- Impact of R&D expenses on performance: Minor
- Date of conclusion of joint research agreement: Unknown
- Counterparty: Yokohama City University
AI要約
Section Heading
This is a notification regarding the conclusion of a joint research agreement with Yokohama City University, a public university corporation. We will jointly conduct efficacy evaluation tests of HGF for CIPN (chemotherapy-induced peripheral neuropathy). The research will be conducted with lecturer Takuya Sato of the Graduate School of Life Nano System Science at Yokohama City University, and if the efficacy of HGF is demonstrated, it is expected to create new treatment strategies. It is noted that the impact on our performance is expected to be minor relative to R&D expenses.
Section 2 Heading
As background, CIPN is a representative side effect of anticancer drug therapy, and there are currently no established effective prevention or treatment methods. HGF has multiple biological activities such as neuroprotection and axonal growth, and is期待されている as a therapeutic for neurodegenerative diseases. Depending on future research results, market opportunities may expand.
CrinklePharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
